Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency, and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“germline mutations in FH cause hereditary leiomyomatosis and renal cell cancer (HLRCC) (7).”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [7]
In the citing paper
“Familial cancer syndromes caused by fumarate hydratase (FH) or succinate dehydrogenase (SDH) deletion suggest that these TCA enzymes can behave as classical tumor suppressors.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Tomlinson et al., 2002
In the citing paper
“Similarly, germline mutations in the broadly expressed enzyme fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma, a familial syndrome of uterine and cutaneous leiomyomas and kidney cancer, without susceptibility to more common tumors (11).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [11]
In the citing paper
“In 2001, mutation of fumarate hydratase leading to its inactivation was discovered in renal cell cancer129. Mutation of this enzyme leads to fumarate accumulation not only in skin cancer and uterine leiomyomas but also in breast, bladder, and Leydig cell tumors130.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [130]
In the citing paper
“Consistently, heterozygous germline mutations in genes encoding the TCA cycle enzymes involved in the breakdown of these metabolites—SDH and FH—have been shown to facilitate the pathogenesis of certain rare cancers (e.g., paragangliomas) and inherited cancer-predisposition syndromes (181, 182, 183).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [183]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon.
Liochev, S. I., & Fridovich, I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5892 · Cited by 239
The VHL tumour-suppressor gene paradigm
Kaelin, W. G., & Maher, E. R. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01558-3 · Cited by 213 · cited 1×
“, individuals with von Hippel–Lindau syndrome are predisposed to both phaeochromocytomas and renal carcinoma”
BackgroundKiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., Arola, J., Pukkala, E., Sistonen, P., Herva, R., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61757-9 · Cited by 209
Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich, A., Rötig, A., Landrieu, P., & Rustin, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117261 · Cited by 160
Alam, N. A., Bevan, S., Churchman, M., Barclay, E., Barker, K., Jaeger, E. E. M., Nelson, H. M., Healy, E., Pembroke, A. C., Friedmann, P. S., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320124 · Cited by 160
Familial predisposition to uterine leiomyomas
Vikhliaeva, E. M., Сагдуллаевна, Х. З., & Nd, F. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02533-i · Cited by 152 · cited 1×
“gif" NDATA ITEM> ]> Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesi”
Background
Cited by
Items 201–300 of 1,000
Brière, J.-J., Favier, J., Bénit, P., Ghouzzi, V. E., Lorenzato, A., Rabier, D., Di Renzo, M. F., Gimenez-Roqueplo, A.-P., & Rustin, P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi359 · Cited by 152
“The discovery that a mutation in fumarase can trigger cutaneous and uterine leiomyomatosis and renal cancer (23) suggested that blocking the metabolic step involving SDH and fumarase is crucial for tumourigenesis (24).”
BackgroundHypothesis: Environmental regulation of 5-hydroxymethylcytosine by oxidative stress
Chia, N., Wang, L., Lu, X., Senut, M.-C., Brenner, C. A., & Ruden, D. M. (2011) · Epigenetics · doi:10.4161/epi.6.7.16461 · Cited by 157
Dual roles of NRF2 in tumor prevention and progression: Possible implications in cancer treatment
Moon, E. J., & Giaccia, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.009 · Cited by 160
“Fumarate accumulation due to fumarate hydratase (FH)-deficiency results in hereditary leiomyomatosis renal cell carcinoma (HLRCC) and type-2 papillary renal carcinoma (pRCC) [76].”
Sharma, L. K., Fang, H., Liu, J., Vartak, R., Deng, J., & Bai, Y. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr395 · Cited by 157
“In particular, mutations in the nuclear DNA-encoded subunits of respiratory complex II or succinate dehydrogenase (32) and other components of tricarboxylic acid (TCA) cycle, such as fumarate hydratase (33) and isocitrate dehydrogenase (34), have been identified in different cancers.”
BackgroundBiology and treatment of renal tumours in childhood
Brok, J. S., Treger, T. D., Gooskens, S. L. M., van den Heuvel‐Eibrink, M. M., & Pritchard‐Jones, K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.005 · Cited by 182
“Children with germline mutations of two tricarboxylic acid (Krebs) cycle genes, fumarate hydratase (FH) and succinate dehydrogenase (SDH), are also susceptible to RCC [79].”
BackgroundSchultz, K. A. P., Rednam, S. P., Kamihara, J., Doros, L., Achatz, M. I., Wasserman, J. D., Diller, L. R., Brugières, L., Druker, H., Schneider, K. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0629 · Cited by 158
“Pathogenic variants in FH can lead to significantly low or absent FH enzyme levels in tumors (41).”
BackgroundInfluentialOoi, A., Dykema, K., Ansari, A., Petillo, D., Snider, J., Kahnoski, R., Anema, J., Craig, D., Carpten, J., Teh, B.-T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3227 · Cited by 159
“Individuals who inherit a germline mutation in the fumarate hydratase (FH) gene are predisposed to developing PRCC2 (4).”
BackgroundThe TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
Pollard, P., Wortham, N., & Tomlinson, I. (2003) · Annals of Medicine · doi:10.1080/07853890310018458 · Cited by 159
The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy
Tal, R., & Segars, J. H. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt042 · Cited by 159
“HLRCC results from an inactivating germline mutation in the fumarate hydratase (FH) gene, which encodes the Krebs cycle enzyme which acts as a classical tumor suppressor (Tomlinson et al., 2002; Alam et al., 2003).”
BackgroundInhibition of Mitochondrial Aconitase by Succination in Fumarate Hydratase Deficiency
Ternette, N., Yang, M., Laroyia, M., Kitagawa, M., O’Flaherty, L., Wolhulter, K., Igarashi, K., Saito, K., Kato, K., Fischer, R., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.02.013 · Cited by 158
“(E and F) CE-TOFMS analyses of fumarate concentrations in HLRCC tumors (E) and in Fh1-deficient kidneys.”
InfluentialPromoter Hypermethylation Profile of Kidney Cancer
Dulaimi, E., de Cáceres, I. I., Uzzo, R. G., Al‐Saleem, T., Greenberg, R. E., Polascik, T. J., Babb, J. S., Grizzle, W. E., & Cairns, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0175 · Cited by 172
“The MET oncogene and the fumarate hydratase (FH) tumor suppressor gene have been identified as predisposition genes for hereditary papillary renal cancer (12, 13), and Received 1/28/04; revised 3/23/04; accepted 3/29/04.”
BackgroundHereditary leiomyomatosis and renal cell carcinoma
Schmidt, L. S., & Linehan, W. M. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s42097 · Cited by 168
“This disorder is characterized by germline mutations in the gene for the TCA cycle enzyme – FH. Germline FH mutation testing is important for all at-risk family members, since the early onset renal tumors that develop in HLRCC patients can progress and metastasize even when small.”
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Lehtonen, H. J. (2011) · Familial Cancer · doi:10.1007/s10689-011-9428-z · Cited by 160
“Only a few cases of tumors have been reported in the heterozygous relatives of the FHD patients, including one possible RCC case [4, 23, 63, 64].”
BackgroundInfluentialKiuru, M. H., Lehtonen, R., Arola, J. T., Salovaara, R., Järvinen, H., Aittomäki, K., Sjöberg, J., Visakorpi, T., Knuutila, S., Isola, J. J., et al. (2002) · PubMed · Cited by 156
Genetic insights into OXPHOS defect and its role in cancer
Chandra, D., & Singh, K. K. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.023 · Cited by 151
“In addition, hereditary mutations in the Krebs's cycle enzyme fumarate hydratase (FH) lead to leiomyomas, uterine fibroids, and renal cell carcinoma [43].”
Fumarate Hydratase–deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings
Harrison, W. J., Andrici, J., Maclean, F. M., Ghahan, R. M., Farzin, M., Sioson, L., Toon, C. W., Clarkson, A., Watson, N., Pickett, J., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000573 · Cited by 152
Alam, N., Olpin, S. E., & Leigh, I. M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06678.x · Cited by 151
Linehan, W. M., Pinto, P. A., Srinivasan, R., Merino, M. J., Choyke, P. L., Choyke, L. T., Coleman, J., Toro, J. R., Glenn, G. M., Vocke, C. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1870 · Cited by 164
Redox control of glutamine utilization in cancer
Alberghina, L., & Gaglio, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.513 · Cited by 147
The metabolic basis of kidney cancer
Linehan, W. M., & Ricketts, C. J. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.002 · Cited by 144
Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling
Quade, B. J., Wang, T., Sornberger, K., Cin, P. D., Mutter, G. L., & Morton, C. C. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20018 · Cited by 150
“Recently, an enzyme of the citric acid cycle, fumarate hydratase, was implicated in familial cutaneous leiomyomatosis by genetic linkage and mutation analysis (Tomlinson et al., 2002).”
BackgroundTubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci
Smith, S. C., Trpkov, K., Chen, Y., Mehra, R., Sirohi, D., Ohe, C., Cani, A. K., Hovelson, D. H., Omata, K., McHugh, J. B., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000719 · Cited by 150
“Subsequently, building on findings of a group of such families also affected by an aggressive RCC, the association of this type of RCC with MCUL was reported in 2001, renamed HLRCC (29), and mapped to a locus on the long arm of chromosome 1 shown to be the locus of FH (30).”
BackgroundChinopoulos, C. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23196 · Cited by 143
“…pathway in which cancer finds metabolic support when growing in hypoxic environments, while also exhibiting a number of defects in the electron transport chain (Tomlinson et al., 2002; Hao et al., 2009; Linehan et al., 2010; Weinberg et al., 2010), rendering its harboring mitochondria defective.”
BackgroundGardie, B., Remenieras, A., Kattygnarath, D., Bombled, J., Lefèvre, S.-H., Perrier-Trudova, V., Rustin, P., Barrois, M., Slama, A., Avril, M., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.085068 · Cited by 160
“7 The function of FH is then consistent with the function of tumour suppressor genes.(6) As part of the French National Cancer Institute (INCa) ‘Inherited predispositions to kidney cancer ’ network, we performed the first comprehensive genetic and functional analysis of FH in a large series of patients with phenotypes…”
BackgroundInfluentialMolecular targets for cancer chemoprevention
William, W. N., Heymach, J. V., Kim, E. S., & Lippman, S. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2663 · Cited by 157
“cgi?id=605839">hereditary leiomyomatosis and renal cell carcinoma, results from mutations in the fumarate hydratase ( FH ) gen”
BackgroundInborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 146
“Similar to SDH in hPGL, enzymatic activity of FH is absent in HLRCC tumors and loss of the wild-type allele is observed in the majority of tumors [19].”
BackgroundNew and emerging renal entities: a perspective post‐ WHO 2016 classification
Trpkov, K., & Hes, O. (2018) · Histopathology · doi:10.1111/his.13727 · Cited by 158
Morandi, A., Taddei, M. L., Chiarugi, P., & Giannoni, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00040 · Cited by 157
The role of complex II in disease
Hoekstra, A. S., & Bayley, J. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.11.005 · Cited by 154
Joint mouse–human phenome-wide association to test gene function and disease risk
Wang, X., Pandey, A. K., Mulligan, M. K., Williams, E. G., Mozhui, K., Li, Z., Jovaisaite, V., Quarles, L. D., Xiao, Z., Huang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10464 · Cited by 147
Muller, M., Ferlicot, S., Guillaud-Bataille, M., Teuff, G. L., Genestie, C., DeVeaux, S., Slama, A., Poulalhon, N., Escudier, B. J., Albiges, L. K., et al. (2017) · Clinical Genetics · doi:10.1111/cge.13014 · Cited by 148
“It was traditionally considered that RCC of papillary type 2 histology was specifically associated with the syndrome with a lifetime risk estimated at around 15%.(2,3,6) Recent pathological studies have however shown that unclassified RCC with high grade or papillary pattern and tubulocystic (TC) RCC are also observed…”
BackgroundZhang, J., Yao, M., Xia, S., Zeng, F., & Liu, Q. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00682-7 · Cited by 126
Uterine stem cells: from basic research to advanced cell therapies
Santamaria, X., Mas, A., Cervelló, I., Taylor, H., & Simon, C. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy028 · Cited by 147
Inactivation of BHD in sporadic renal tumors.
Khoo, S. K., Kahnoski, K., Sugimura, J., Petillo, D., Chen, J., Shockley, K., Ludlow, J. W., Knapp, R., Giraud, S., Richard, S., et al. (2003) · PubMed · Cited by 156
Adult Leydig Cell Tumors of the Testis Caused by Germline Fumarate Hydratase Mutations
Carvajal-Carmona, L. G., Alam, N. A., Pollard, P. J., Jones, A. M., Barclay, E., Wortham, N., Pignatelli, M., Freeman, A., Pomplun, S., Ellis, I., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0183 · Cited by 145
“The locations of three other FH mutations found in vivo (16, 19) are shown in yellow as either spacefill view on the same subunit as M411 (residue 422) or backbone view on the other subunit (residues 322 and 323).”
BackgroundMitochondria in cancer: at the crossroads of life and death
Fogg, V. C., Lanning, N. J., & MacKeigan, J. P. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10018 · Cited by 155
Yang, Y., Valera, V. A., Padilla-Nash, H. M., Sourbier, C., Vocke, C. D., Vira, M. A., Abu-Asab, M. S., Bratslavsky, G., Tsokos, M., Merino, M. J., et al. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.08.018 · Cited by 139
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 144
Metabolic alterations in cancer cells and therapeutic implications
Hammoudi, N., Ahmed, K. B. R., García-Prieto, C., & Huang, P. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10267 · Cited by 150
Re‐evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients
Li, Y., Reuter, V. E., Matoso, A., Netto, G. J., Epstein, J. I., & Argani, P. (2017) · Histopathology · doi:10.1111/his.13395 · Cited by 137
Ohe, C., Smith, S. C., Sirohi, D., Divatia, M. K., de Peralta‐Venturina, M., Paner, G. P., Agaimy, A., Amin, M., Argani, P., Chen, Y., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001000 · Cited by 135
“African American 25/32 (78) 2/31 (7) 3/24 (12) Other 4/32 (13) 1/31 (3) 4/24 (17)”
Glutamine Metabolism in Cancer
Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 154
Genetics and epigenetics of renal cell cancer
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Schouten, L. J., Soetekouw, P. M. M. B., de Bruïne, A. P., & van Engeland, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.002 · Cited by 146
Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review
Patel, V. M., Handler, M. Z., Schwartz, R. A., & Lambert, W. C. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.023 · Cited by 135
“For mutation-negative patients with features suggestive of HLRCC, larger deletions or amplifications at the FH locus may occur.(10,23,58,60) Therefore, a quantitative polymerase chain reaction study, multiplex ligation-dependent probe amplification, or gene-targeted microarray may be used to reveal copy number alterat…”
BackgroundIsocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 152
“Abbreviations AITL: angioimmunoblastic T cell lymphoma; AML: acute myeloid leukemia; ccRCC: clear‑cell renal cell carcinoma; (D)‑2HG: (d)‑2‑hydroxyglutarate; D2HGA2: type II d‑hydroxyglutaric aciduria; D2HGD: (d)‑2‑hydroxyglutarate dehydrogenase enzyme; ETC: electron transport chain; FAs: fatty acids; FH: fumarate hyd…”
BackgroundInfluentialMitochondria, from cell death to proliferation
Rustin, P. (2002) · Nature Genetics · doi:10.1038/ng0402-352 · Cited by 149
Sanz‐Ortega, J., Vocke, C. D., Stratton, P., Linehan, W. M., & Merino, M. J. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825ec16f · Cited by 133
“2 Affected individuals harbor a germline heterozygous lossof-function mutation of the fumarate hydratase (FH) gene.(1,3,4) HLRCC is also known as multiple cutaneous and uterine leiomyomatosis syndrome.”
BackgroundJoseph, N. M., Solomon, D. A., Frizzell, N., Rabban, J. T., Zaloudek, C. J., & Garg, K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000520 · Cited by 136
“1 HLRCC predisposes patients to multiple cutaneous and uterine leiomyomas and renal cell carcinoma.(1) It is assumed that tumors develop due to a second hit with loss of the second allele, frequently by loss of heterozygosity.”
BackgroundOxidative metabolism in cancer growth
Ristow, M. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232892.43921.98 · Cited by 130
“enzymes linked to tumor growth are complex I deficiencies [90,91] (Fig. 1T), as well as fumarate hydratase deficiencies [ 92 ,93] (Fig. 1U).”
BackgroundCardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 139
Mitochondrial complex I is deficient in renal oncocytomas
Simonnet, H., Demont, J., Pfeiffer, K., Guenaneche, L., Bouvier, R., Brandt, U., Schägger, H., & Godinot, C. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg109 · Cited by 138
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 147
Linehan, W. M., & Zbar, B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.006 · Cited by 129
Thierbach, R., Schulz, T. J., Isken, F., Voigt, A., Mietzner, B., Drewes, G., von Kleist-Retzow, J.-C., Wiesner, R. J., Magnuson, M. A., Puccio, H., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi410 · Cited by 127
“As previously discussed for a similar apparent inconsistency in fumarate hydratase deficient individuals (50), Friedreich ataxia patients typically exhibit a decreased life expectancy of 38 years on average, which may prevent tumors to evolve into a clinically visible state.”
Backgroundvon Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney Cancer
Maynard, M. A., & Ohh, M. (2004) · American Journal of Nephrology · doi:10.1159/000075346 · Cited by 123
“In hereditary leiomyoma patients, germline mutations of the fumarase gene followed by a second somatic inactivation of the remaining wild-type allele have been implicated in the pathogenesis of this papillary type 2 RCC [”
BackgroundRenal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Costa, L. J., & Drabkin, H. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1404 · Cited by 142
“Another pathway of HIF accumulation and RCC developmentinvolvesKrebscycleenzymemutations:succinatedehydrogenase (SDH)-B mutations [16] cause clear-cell RCC, while mutations of fumarate hydratase [ 17 ] cause typeIIpapillarycancer.InSDHmutations,accumulationof succinate directly inhibits proline hydroxylase and HIFleve…”
BackgroundClague, J., Lin, J. M., Cassidy, A., Matin, S. F., Tannir, N. M., Tamboli, P., Wood, C. G., & Wu, X. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0601 · Cited by 126
“Although the vast majority of RCC occurs sporadically, several hereditary conditions, including von Hippel– Lindau syndrome (24), hereditary papillary renal cancer related to germline mutations, activation of the MET and the FH gene (25), and Birt-Hogg-Dube syndrome (26), have been linked to RCC development.”
BackgroundAlterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K.-L., & Xiong, Y. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 119
“Mutations targeting the FH gene in tumors were first found in inherited uterine fibroids, skin leiomyomata, and papillary renal cell cancer, [49] and subsequently in leydig cell tumors [50].”
BackgroundLactic Acidosis: Recognition, Kinetics, and Associated Prognosis
Vernon, C., & LeTourneau, J. L. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2009.12.007 · Cited by 126
Lifestyle Factors, Exposures, Genetic Susceptibility, and Renal Cell Cancer Risk: A Review
Moore, L. E., Wilson, R. T., & Campleman, S. L. (2005) · Cancer Investigation · doi:10.1081/cnv-200055962 · Cited by 135
Pålsson‐McDermott, E. M., & O'Neill, L. A. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.004 · Cited by 137
Kovac, M., Navas, C., Horswell, S., Salm, M., Bardella, C., Rowan, A., Stares, M., Castro-Giner, F., Fisher, R., de Bruin, E. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7336 · Cited by 121
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma
Sandberg, A. A. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.08.025 · Cited by 129
SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery
Saxena, N., Maio, N., Crooks, D. R., Ricketts, C. J., Yang, Y., Wei, M.-H., Fan, T. W. ‐., Lane, A. N., Sourbier, C., Singh, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv287 · Cited by 133
Epidemiology and Staging of Renal Cell Carcinoma
Ridge, C. A., Pua, B. B., & Madoff, D. C. (2014) · Seminars in Interventional Radiology · doi:10.1055/s-0033-1363837 · Cited by 122
Campbell, S. C., & Lane, B. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00049-9 · Cited by 122
A chemoproteomic portrait of the oncometabolite fumarate
Kulkarni, R. A., Bak, D. W., Wei, D., Bergholtz, S. E., Briney, C. A., Shrimp, J. H., Alpsoy, A., Thorpe, A. L., Bavari, A. E., Crooks, D. R., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0217-y · Cited by 120
“7 8 Discussion 9 10 The discovery of hereditary cancers driven by TCA cycle mutations provided some of the first 11 evidence that metabolites themselves could fuel tumorigenic signaling.(1-3) Recent data indicates that 12”
McCammon, M. T., Epstein, C. B., Przybyla-Zawislak, B., McAlister-Henn, L., & Butow, R. A. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-07-0422 · Cited by 119
“The magnitude of the expression changes in the -ketoglutarate dehydrogenase mutants appears to be close to but less than the maximal changes in expression reported in heme auxotrophs or by mutations in HAP1 or ROX1 (Kwast et al., 2002; Ter Linde and Steensma, 2002 ).”
BackgroundGenetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 132
Mitochondria as a target in cancer treatment
Liu, Y., & Shi, Y. (2020) · MedComm · doi:10.1002/mco2.16 · Cited by 130
Bayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 131
Pal, S. K., Ali, S. M., Yakirevich, E., Geynisman, D. M., Karam, J. A., Elvin, J. A., Frampton, G. M., Huang, X., Lin, D. I., Rosenzweig, M. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.033 · Cited by 119
“One pathogenic FH missense mutation was reported (R233H) [17]; the remaining FH mutations were loss-of-function truncation mutations.”
BackgroundPheochromocytomas: The (pseudo)-hypoxia hypothesis
Favier, J., & Gimenez‐Roqueplo, A. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.10.004 · Cited by 124
Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
Valcárcel-Jiménez, L., & Frezza, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02412-w · Cited by 127
Targeting Cancer Metabolism - Revisiting the Warburg Effects
Tran, Q., Lee, H., Park, J., Kim, S.-H., & Park, J. (2016) · Toxicological Research · doi:10.5487/tr.2016.32.3.177 · Cited by 112
Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA
Gorelick, A. N., Kim, M., Chatila, W. K., La, K., Hakimi, A. A., Berger, M. F., Taylor, B. S., Gammage, P. A., & Reznik, E. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00378-8 · Cited by 113
Desideri, E., Vegliante, R., & Ciriolo, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.023 · Cited by 124
Porporato, P. E., Payen, V. L., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2100-2 · Cited by 121
Fumarase: a paradigm of dual targeting and dual localized functions
Yogev, O., Naamati, A., & Pines, O. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08359.x · Cited by 116
Huyck, K. L., Panhuysen, C. I. M., Cuenco, K. T., Zhang, J., Goldhammer, H., Jones, E. S., Somasundaram, P., Lynch, A. M., Harlow, B. L., Lee, H., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.05.038 · Cited by 115
Tumor metabolism as modulator of immune response and tumor progression
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.009 · Cited by 125
The role of mitochondria in pulmonary vascular remodeling
Dromparis, P., Sutendra, G., & Michelakis, E. D. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0670-x · Cited by 118
“Mutations in fumarate hydratase [ 45 ] and succinate dehydrogenase [46, 47] (Krebs cycle enzymes) have been identified in renal cell carcinomas and paragangliomas.”
BackgroundDeficient H2A.Z deposition is associated with genesis of uterine leiomyoma
Berta, D. G., Kuisma, H., Välimäki, N., Räisänen, M., Jäntti, M., Pasanen, A. M., Karhu, A., Tolvanen, J., Taira, A., Cajuso, T., et al. (2021) · Nature · doi:10.1038/s41586-021-03747-1 · Cited by 115
Chen, J., Lui, W., Vos, M. D., Clark, G. J., Takahashi, M., Schoumans, J., Khoo, S. K., Petillo, D., Lavery, T. T., Sugimura, J., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00269-1 · Cited by 136
Pillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 125
Immunomic analysis of human sarcoma
Lee, S., Obata, Y., Yoshida, M., Stockert, E., Williamson, B., Jungbluth, A. A., Chen, Y., Old, L. J., & Scanlan, M. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437972100 · Cited by 113
Hereditary kidney cancer: Unique Opportunity for Disease‐based Therapy
Linehan, W. M., Pinto, P. A., Bratslavsky, G., Pfaffenroth, E. C., Merino, M. J., Vocke, C. D., Toro, J. R., Bottaro, D. P., Neckers, L., Schmidt, L. S., et al. (2009) · Cancer · doi:10.1002/cncr.24230 · Cited by 112
“The susceptibility gene for HLRCC encodes the Krebs cycle enzyme, FH.(57) Mutations of the FH gene have been detected in >90% of HLRCC kindreds.”
BackgroundMäkinen, N., Kämpjärvi, K., Frizzell, N., Bützow, R. C., & Vahteristo, P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0672-1 · Cited by 112
“N107T) has been reported in six UK HLRCC families [14], supporting the pathogenicity of the mutation.”
BackgroundOrgan-Specific Cancer Metabolism and Its Potential for Therapy
Elia, I., Schmieder, R., Christen, S., & Fendt, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_10 · Cited by 129
“provide evidence that certain metabolic preconditions such as mutations in the enzyme fumarate hydratase, diabetes, or obesity are correlated with a significantly increased cancer risk [3-5].”
Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation
Brière, J.-J., Favier, J., Gimenez-Roqueplo, A.-P., & Rustin, P. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00216.2006 · Cited by 109
“It was further shown that, far from being restricted to rare cases of encephalopathy, the total loss of FH unexpectedly results in uterine fibroids, skin leiomyomata, and papillary renal cell cancer (58).”
BackgroundNew Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
Srinivasan, R., Ricketts, C. J., Sourbier, C., & Linehan, W. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2993 · Cited by 117
“HLRCC is characterized by germline mutation of the gene for the Krebs cycle enzyme, FH (62).”
BackgroundKerins, M. J., Milligan, J., Wohlschlegel, J. A., & Ooi, A. (2018) · Cancer Science · doi:10.1111/cas.13701 · Cited by 114
“HLRCC patients harbor a germline, inactivating mutation to one of the FH alleles.(1) Loss of heterozygosity at the FH locus, which results in the complete loss of FH enzymatic function, is invariably found in the diseased tissues, solidifying FH inactivation as the tumor‐initiating event in HLRCC.”
BackgroundSpiegel, R., Pines, O., Ta‐Shma, A., Burak, E., Shaag, A., Halvardson, J., Edvardson, S., Mahajna, M., Zenvirt, S., Saada, A., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.01.009 · Cited by 111
O'Flaherty, L., Adam, J., Heather, L. C., Zhdanov, A. V., Chung, Y.-L., Miranda, M. X., Croft, J., Olpin, S., Clarke, K., Pugh, C. W., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq305 · Cited by 109
Muller, M., Guillaud-Bataille, M., Salleron, J., Genestie, C., Deveaux, S., Slama, A., Paillerets, B. B., Richard, S., Benusiglio, P. R., & Ferlicot, S. (2018) · Modern Pathology · doi:10.1038/s41379-018-0017-7 · Cited by 110
Kinch, L., Grishin, N. V., & Brugarolas, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.005 · Cited by 106
“Heterozygous germline FH mutations result in hereditary leiomyomatosis and renal cell cancer (HLRCC), a syndrome characterized by smooth muscle tumors and papillary renal cell carcinoma type 2 (pRCC-2) (Tomlinson et al., 2002).”
BackgroundMitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts
Samper, E., Nicholls, D. G., & Melov, S. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00062.x · Cited by 108
The Metabolic Alterations of Cancer Cells
Sciacovelli, M., Gaude, E., Hilvo, M., & Frezza, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00001-7 · Cited by 116
Evenepoel, L., Papathomas, T. G., Krol, N. M. G., Korpershoek, E., de Krijger, R. R., Persu, A., & Dinjens, W. N. M. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.162 · Cited by 115
Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM)
Bruntz, R. C., Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.776054 · Cited by 114
“Metabolic enzymes are frequently mutated in certain cancers such as SDH in gastrointestinal, renal cell carcinomas, and paraganglioma tumors (83), IDH in GBM (84), and FH in renal cell cancers (85).”
Background
Metadata
- Authors
- The Multiple Leiomyoma Consortium
- Venue
- Nature Genetics
- Published
- 2002-02-25
- Volume
- 30
- Issue
- 4
- Pages
- 406-410
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1967291345
- Cited by
- 1,635
- References
- 17
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 57 · 2022: 65 · 2021: 80 · 2020: 93 · 2019: 86 · 2018: 81 · 2017: 90 · 2016: 106 · 2015: 89 · 2014: 85 · 2013: 82 · 2012: 82
- FWCI
- 56.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.S. Public Health Service (U59309)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fumarate hydratase, FH gene, germline mutations, uterine fibroids, cutaneous leiomyoma, papillary renal cell carcinoma, cancer susceptibility, tumor suppressor, fumarate hydratase deficiency, compound heterozygosity, TCA cycle, fibroid pathogenesis
- MeSH terms
- Alleles, Carcinoma, Papillary, Carcinoma, Renal Cell, Chromosomes, Human, Pair 1, Exons, Female, Fumarate Hydratase, Genes, Dominant, Genetic Markers, Humans, Kidney Neoplasms, Leiomyoma, Male, Mutation, Pedigree, Recombination, Genetic, Uterine Neoplasms, Gene Deletion, In Situ Hybridization, Fluorescence, Sequence Analysis, DNA, Germ-Line Mutation, Leiomyoma, Epithelioid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.